X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles, administered via intratumoral injection and activated by radiotherapy. It is being evaluated for the treatment of recurrent non-small cell lung cancer.
Lead Product(s): Hafnium Oxide
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2024
Details:
Nanobiotx received the initial milestone payment, marking a significant step in the advancement of the pivotal Phase 3 study assessing the potential first-in-class radio enhancer NBTXR3 (cetuximab) for elderly patients diagnosed with head and neck cancer.
Lead Product(s): Hafnium Oxide
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: $2,730.0 million Upfront Cash: $60.0 million
Deal Type: Licensing Agreement January 29, 2024
Details:
Under the agreement, LianBio will assign to Janssen exclusive rights to develop and commercialize first-in-class radio enhancer NBTXR3 (hafnium oxide) in China, South Korea, Singapore, and Thailand for the treatment of locally advanced head and neck squamous cell cancers.
Lead Product(s): Hafnium Oxide
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 26, 2023
Details:
The company intends to use the proceeds for the supply of NBTXR3, a novel radioenhancer composed of functionalized hafnium oxide crystalline nanoparticles, to advance the Company’s Phase 3 in the US and the EU for the treatment of locally advanced head and neck cancers.
Lead Product(s): Hafnium Oxide,Cetuximab
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies LLC
Deal Size: $34.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 07, 2023
Details:
The company intends to use the proceeds for the supply of NBTXR3, a novel radioenhancer composed of functionalized hafnium oxide crystalline nanoparticles, to advance the Company’s Phase 3 in the US and the EU for the treatment of locally advanced head and neck cancers.
Lead Product(s): Hafnium Oxide,Cetuximab
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies LLC
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 02, 2023
Details:
NBTXR3 (hafnium oxide) is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy.
Lead Product(s): Hafnium Oxide
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2023
Details:
Under the agreement, Nanobiotix will grant Janssen a worldwide license for the development and commercialization of an investigational, potential first-in-class radioenhancer NBTXR3 (hafnium oxide), currently being evaluated in several studies across solid tumor indications.
Lead Product(s): Hafnium Oxide,Cetuximab
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: $3,610.0 million Upfront Cash: $60.0 million
Deal Type: Licensing Agreement July 10, 2023
Details:
NBTXR3 (hafnium oxide nanoparticles) is a novel, potentially first-in-class oncology product that is administered via one-time intratumoral injection and activated by radiotherapy.
Lead Product(s): Hafnium Oxide,Cetuximab
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2022
Details:
NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy.
Lead Product(s): Hafnium Oxide
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy.
Lead Product(s): Hafnium Oxide,Pembrolizumab
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2022
Details:
NBTXR3 (hafnium oxide) is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles administered via one-time intratumoral injection and activated by radiotherapy.
Lead Product(s): Hafnium Oxide,Pembrolizumab
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
Details:
Data from study in 12 evaluable patients with stage 4 disease showed that combining NBTXR3 (hafnium oxide) with concurrent chemoradiation was feasible, had a favorable safety profile, produced a 100% disease control rate, and an ORR of 58.3%.
Lead Product(s): Hafnium Oxide,Cetuximab
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2022
Details:
NBTXR3 (hafnium oxide), is a novel, potentially first-in-class oncology product, composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy.
Lead Product(s): Hafnium Oxide,Cetuximab
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
Nanobiotix aims to address the significant unmet need in cancer immunotherapy by combining NBTXR3 plus radiotherapy with anti-PD-1 in advanced cancers to potentially improve treatment outcomes for patients regardless of their prior exposure to immune checkpoint inhibitors.
Lead Product(s): Hafnium Oxide,Pembrolizumab
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2021
Details:
LianBio to collaborate in the development of NBTXR3, and contribute to enrollment in five future global registrational studies across several tumor types and therapeutic combinations including immunotherapy.
Lead Product(s): Hafnium Oxide,Pembrolizumab
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: LianBio
Deal Size: $240.0 million Upfront Cash: $20.0 million
Deal Type: Partnership May 11, 2021
Details:
The combination therapy of NBTXR3 + XRT + anti-PD-1 + anti-LAG3 + anti-TIGIT (Combo therapy) significantly promoted the proliferation activity of CD8+ T cells, improved local and distant tumor control, and increased survival rate.
Lead Product(s): Hafnium Oxide,Undisclosed
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2021
Details:
Two studies have received ‘Safe to Proceed’ notice from the FDA. A phase II study of NBTXR3 activated by radiation and combined with pembrolizumab for recurrent/metastatic head & neck squamous cell cancer and a phase II study of reirradiation with NBTXR3 in head & neck cancer.
Lead Product(s): Hafnium Oxide,Pembrolizumab
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2020
Details:
NBTXR3 activated by radiation therapy produced a strong abscopal effect without a checkpoint inhibitor combination. NBTXR3 activated by radiation therapy stimulated adaptive antitumor immunity.
Lead Product(s): Hafnium Oxide,Undisclosed
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
Data show that, to date, administration of NBTXR3 via intra-tumoral injection has been feasible and well tolerated in all patients (head and neck cancer, lung metastasis, and liver metastasis).
Lead Product(s): Hafnium Oxide,Nivolumab
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
Details:
Nanobiotix global development plan for first-in-class radioenhancer NBTXR3 across several solid tumor indications proceeds as planned with focus on priority pathways in head and neck cancer and immunotherapy .
Lead Product(s): Hafnium Oxide
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
Phase I Study of Intratumoral NBTXR3 in Combination with anti-PD-1 in Patients with Advanced Cancers will be presented at the conference.
Lead Product(s): Hafnium Oxide,Undisclosed
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2020
Details:
First patient injected in phase I trial evaluating NBTXR3 activated by radiation therapy for patients with pancreatic cancer at The University of Texas MD Anderson Cancer Center in clinical collaboration with Nanobiotix.
Lead Product(s): Hafnium Oxide
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
The financing will help ensure the company have the necessary resources to continue achieving its goals to advance the development of NBTXR3.
Lead Product(s): Hafnium Oxide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: HSBC
Deal Size: $11.1 million Upfront Cash: Undisclosed
Deal Type: Financing June 08, 2020
Details:
NBTXR3 has been administered to 40 patients in the trial and was well tolerated, maintaining the safety profile observed in the dose escalation part of the phase I study.
Lead Product(s): Hafnium Oxide,Cisplatin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020
Details:
The trial is a phase I dose escalation study evaluating the safety & feasibility of NBTXR3 activated by radiation therapy in locally advanced or borderline-resectable pancreatic ductal adenocarcinoma.
Lead Product(s): Hafnium Oxide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 07, 2020
Details:
The Company remains in position to deliver data from its priority pathways in head and neck cancer and immuno-oncology (I/O) on schedule.
Lead Product(s): Hafnium Oxide,Cisplatin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2020
Details:
The U.S. FDA concluded that investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, meets the criteria for a Fast Track development program.
Lead Product(s): Hafnium Oxide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2020
Details:
NANOBIOTIX will continue to prioritize its registration pathway in the US and EU for the treatment of head and neck cancers, while also working to advance the Nanobiotix immuno-oncology program.
Lead Product(s): Hafnium Oxide,Cisplatin,Pembrolizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
